#Venetoclax + #obinutuzumab just approved frontline for #CLL in Brazil. Important option for patients not eligible for intensive Tx. Nice to see quicker regulatory approvals in Brazil. Interesting how all will be incorporated into practice.

#CLL SM U.S. FDA EU Medicines Agency MOC Brasil

If you or a loved one have been diagnosed with epilepsy, you may be curious what rescue treatments can be used in an emergency. We gathered the basics so you can learn the most important information about rescue epilepsy treatments in one place.

#venetoclax - #obinutuzumab or #venetoclax - #ibrutinib in 1L #CLL ?

Its like a haematologists version of the Messi vs Ronaldo debate...

Amazing times in #CLL . #blooducation #CLL 14 #CLL sm

Stop by our poster #1562 Session 642. #cllsm #PROs to learn about the #QOL results from ECOG-ACRIN Cancer Research Group E1912. Continuous ibrutinib use did not affect long term QOL. Lynne I Wagner PhD Martin S. Tallman, MD Mark Litzow @anthonymatomd UW Health | Carbone Cancer Center

State of the art 2019 update on #CLL by Dr. Jennifer Brown Dana-Farber Society of Hematologic Oncology (SOHO) #Soho2019 #Cllsm

These cranberry-orange fruit bars to help support your immune system, reduce the risk of infections, help brain function, and support heart health: buff.ly/3p4V96e

#HealthTreeCLL #CLL #cllsm #chroniclymphocyticleukemia #healthyrecipe

Big change to NCCN guidelines which now include pirtobrutinib for double exposed CLL pts - hopefully this helps with insurance coverage for pts who aren’t able to do clinical trials #cllsm

Thank you to everyone who came and chatted to me about my poster, am so pleased the #iwCLL2019 delegates are so enthused by our work at Leukaemia Care (sorry about the awful photo everyone, I didn't have Zack Pemberton-Whiteley (he/him) to take the pic this time!) #cllsm #bloodcancerawarenessmonth

“The biggest lesson I've learned through my MPN journey is to stay as positive as possible.” Watch MPN Hero Jessica Kuhns talk about why she shares her positive mindset with other people living with myeloproliferative neoplasms (MPNs). #voicesofmpn #MPNSM

Dr. Furman making sense of ibrutinib discontinuation in #CLLsm during #GDUHEM . ⁦Great Debates & Updates⁩

My #EHA2023 highlights: 1. ⁦Othman Al-Sawaf⁩ reporting the up date of the #CLL 14 trial. Continued benefit for #venetoclax plus #obinutuzumab in 1L treatment of #CLL .

Great educational session on #CLLsm #MRD at #EHA2022 with Andy Rawstron and Paolo Ghia

A lot of uncertainty despite very interesting trial designs with MRD to stop or resume treatment. A reminder of how new therapies can push biomarkers forward and backwards...

Dr Matt Davids Matthew Davids, MD, MMSc giving an excellent talk on venetockax resistance mechanisms in CLL at #LymphomaMyeloma2019 MCL-1 is an attractive next target #cllsm

Dr. Javier Pinilla giving a #cll update ⁦FLASCO⁩ 2021 Fall meeting. Always top-notch lectures! #cll sm #lymsm ⁦Moffitt Cancer Center⁩ ⁦Luis E Raez⁩ ⁦Chakra Chaulagain MD FACP⁩ ⁦Edgardo S. Santos, M.D., FACP⁩ ⁦Rami Manochakian, MD 🇺🇸🇸🇾 #CancerEducation⁩

Honored and excited to attend and speak at the Italian CLL Conference this week. #CLLsm Huntsman Cancer Institute

No surprises here but great to see continued benefit #cllsm #EHA2023 #EHA23

Eddie Cliff Michael Hallek Thomas Eliot Lew Dr Victor Lin Matthew Davids, MD, MMSc David Russler-Germain, MD/PhD International Conference on Malignant Lymphoma Women In Lymphoma - [email protected] Mazyar Shadman, MD MPH Must have been a great talk and discussion! Well- conducted trial for sure. I wonder if newer, less toxic BTK inhibitors can do better? #CLLsm

Avoid meetings and work async in an effort to be fast, nimble, and efficient with Bubbles.

Dusting off the original CLL-IPI
The Lancet Oncology, 2016

Somewhat disappointing to recall that time to first treatment was:
• expressed as 'time' + % in the Y axis
• calculated using Kaplan-Meier instead of cumulative incidence for competitive events

#lymsm #cllsm #RStats

Happening now! Excited for the Q&A session CLL Society Inc. #cllsm

#Hematology #Venetoclax resistance: mechanistic insights and future strategies #CLL #CLL sm cdrjournal.com/article/view/4…

CAR-T in CLL! Serves an unmet clinical need in BTK/Ven refractory patients. Impressive outcomes presented at #ASCO23 . Excited to be a part of this pivotal trial now published in the Lancet!

thelancet.com/journals/lance…

#CLL Frontline treatment per Bill Wierda, MD, PhD @LeukemiaMDA Society of Hematologic Oncology (SOHO) #SOHO2019 #cllsm

Super work- very tough to treat pts enrolled with median 5 prior LOT; 18% CR/CRi including in double refractory subset (prior covBTKi and ven) #cllsm

Beautiful setting for #iwCLL2019 . Just what is needed to get focussed on the debate to come! #CLLsm Looking forward to catching all the updates from VJHemOnc 👈